Filing Flows › MiniMed Group (MMED) › Stock forecast & fair value
MiniMed Group (MMED) stock forecast and fair value
MiniMed Group (MMED) trades at $16.71. 15 analysts' median price target is $27.00 (+62%), from $15.00 to $30.00. Across 10 valuation methods the middle fair value is $22.03 (+32%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $27.78 | $38.71 | $66.46 | +132% |
| EV/Sales vs peers, weighted | $31.85 | $47.09 | $73.51 | +182% |
| EV/Sales vs peers, matched | $16.78 | $22.03 | $40.34 | +32% |
| Residual income | $5.30 | $5.50 | $5.72 | -67% |
| Analysts' price targets | $15.00 | $25.47 | $30.00 | +52% |
| Tangible book (asset value) | $3.60 | $4.50 | $4.50 | -73% |
| Survival-weighted value | $17.92 | $24.38 | $40.82 | +46% |
| Stage-weighted value (decline / turnaround) | $15.48 | $21.21 | $34.84 | +27% |
| Schwartz–Moon simulation (cash can run out) | $0.00 | $6.54 | $19.84 | -61% |
| Net current asset value (net-net) | $0.76 | $1.14 | $1.14 | -93% |
MiniMed Group's latest quarter
MiniMed Group, Q2 2026: revenue $843M (+17% year over year), operating margin 0.6%, net earnings $0, operating cash flow −$49.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MMED stock?
The median of 15 analysts' 12-month targets is $27.00, +62% from $16.71; the range is $15.00 to $30.00. The average rating is buy.
What is MiniMed Group's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $1.14 and $47.09, with a middle value of $22.03 against a price of $16.71. Each method's assumptions are on the page.
Does MiniMed Group usually beat earnings estimates?
It beat the consensus EPS estimate in 33% of the quarters on record.
Is MMED stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.